Cancer Chemotherapy and Pharmacology

, Volume 35, Issue 2, pp 165–168 | Cite as

Vincristine with high-dose etoposide in advanced breast cancer: a phase II trial of the Piedmont Oncology Association

  • Gary W. Thomas
  • Hyman B. Muss
  • Don V. Jackson
  • John McCulloch
  • William Ramseur
  • James McFarland
  • Helena Hoen
  • Michael Pavy
  • Robin Heath
Original Article Vincristine, Etoposide, Chemotherapy, Breast Cancer
  • 24 Downloads

Abstract

Vincristine (VCR) and etoposide (VP-16) have been shown to be synergistic in a murine model, and this combination was studied in a phase II trial. Eligibility required measurable disease, a performance status of 0–2, a life expectancy of ≥2 months, an interval of at least 3 weeks since the receipt of previous radiation therapy or chemotherapy and recovery from related toxicity, no prior treatment with VCR or VP-16, and no more than two prior chemotherapy regimens (only one for treatment of metastatic disease). Treatment consisted of 0.5 mg i.v. (bolus) VCR followed by 200 mg/m2 VP-16 given over 2 h. Both drugs were given daily for 3 consecutive days every 3 weeks (total dose: VCR, 1.5 mg; VP-16, 600 mg/m2). A total of 18 patients with metastatic breast cancer were accured; 14 had adjuvant chemotherapy and 8 had chemotherapy for advanced disease. As judged by International Union Against Cancer (UICC) criteria, one complete response (CR) and three partial responses (PR) were obtained, for a CR+PR rate of 22% (95% confidence interval, 6%–48%). All responders had soft-tissue involvement only. Six patients had stable disease and 8 showed progression. The median time to treatment failure was 3.5 months, and the median survival from study entry was 8.3 months. The major toxicity was myelosuppression, with 9 patients (50%) experiencing a total WBC of <1,000/mm3. Grade 2–3 neurologic toxicity was noted in 6 patients (33%) and grade 3 nausea and vomiting was noted in 5 (28%). The combination of VCR and VP-16 is active in advanced breast cancer but is not convincingly superior to either of these agents used alone.

Key words

Chemotherapy Breast cancer Vincristine Etoposide 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Vaughn CB, Panettiere F, Thigpen T, Bottomley R, Hoogstraten B, Samal B (1981) Phase II evaluation of VP-16-213 in patients with advanced breast cancer: a Southwest Oncology Group study. Cancer Treat Rep 65: 443Google Scholar
  2. 2.
    Bezwoda WR, Seymóur L, Ariad S (1992) High-dose etoposide in treatment of metastatic breast cancer. Nursing Times 49: 104Google Scholar
  3. 3.
    Eddy DM (1992) High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer. J Clin Oncol 10: 657Google Scholar
  4. 4.
    Fraschini G, Holmes FA, Esparza L, Theriault RL, Buzdar AU, Hortobagyi GN (1991) Phase I–II study of high-dose etoposide in patients with refractory breast cancer. Invest New Drugs 9: 365Google Scholar
  5. 5.
    Hainsworth JD, Johnson DH, Frazier SR, Greco FA (1989) Chronic daily administration of oral etoposide — a phase I trial. J Clin Oncol 7: 396Google Scholar
  6. 6.
    Hopkins JO, Jackson DV Jr, White DR, Muss HB, Cooper MR, Stuart JJ, Spurr CL, Wells HB, Richards F (1983) Vincristine by continuous infusion in refractory breast cancer: a phase II study. Am J Clin Oncol 6: 529Google Scholar
  7. 7.
    Jackson DV, White DR, Spurr CL, Hire EA, Pavy MD, Robertson M, Legos HC, McMahan RA (1983) Moderate-dose vincristine infusion in refractory breast cancer. Am J Clin Oncol 9: 376Google Scholar
  8. 8.
    Jackson DV Jr, Long TR, Trahey TT, Morgan TM (1984) Synergistic antitumor activity of vincristine and VP-16-213. Cancer Chemother Pharmacol 13: 176Google Scholar
  9. 9.
    Jackson DV Jr, Long TR, Rice DG, Morgan TM (1986) Combination of vincristine and VP-16-213. Cancer Biochem Biophys 8: 265Google Scholar
  10. 10.
    Jackson DV Jr, Cruz JM, Zekan P, Caponera ME, Spurr CL, White DR, Richards FII, Muss HB (1989) Phase I study of vincristine and escalating doses of etoposide. Invest New Drugs 7: 203Google Scholar
  11. 11.
    Livingston RB, Carter SK (1973) Single agents in cancer chemotherapy. Plenum, New YorkGoogle Scholar
  12. 12.
    Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207Google Scholar
  13. 13.
    Nichols CR (1992) Role of etoposide in treatment of breast cancer. Semin Oncol 19: 67Google Scholar
  14. 14.
    Sledge GW Jr (1991) Etoposide in the management of metastatic breast cancer. Cancer 67: 266Google Scholar
  15. 15.
    Wander H, Rauschning W, Meyer D (1992) Phase II study of etoposide in previously untreated breast cancer patients. Semin Oncol 19 [Suppl 13]: 67Google Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • Gary W. Thomas
    • 1
  • Hyman B. Muss
    • 1
  • Don V. Jackson
    • 1
  • John McCulloch
    • 1
  • William Ramseur
    • 1
  • James McFarland
    • 1
  • Helena Hoen
    • 1
  • Michael Pavy
    • 1
  • Robin Heath
    • 1
  1. 1.Comprehensive Cancer Center of Wake Forest UniversitySection of Hematology and Oncology, Bowman Gray School of Medicine Medical Center BoulevardWinston-SalemUSA

Personalised recommendations